Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.

① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.

cls.cnDec 24 04:16 ET

CanSino Biologics Begins Trial for Tetanus, Diptheria, Acellular Pertussis Shots

MT NewswiresDec 23 01:37 ET

CanSino Biologics Polio Vaccine Trials Gets First Patient Enrollment

MT NewswiresDec 23 01:29 ET

Announcement Highlights | GTJA has been approved to be the major Shareholder of HAITONG SEC's related Overseas subsidiaries; CATHAY PAC AIR's passenger carried in November increased by about 20% year-on-year.

CATHAY PAC AIR's passenger carried in November increased by approximately 20% year-on-year; Connet Optical plans to issue 53.325 million placement shares at a discount of about 19.98% to Goertek in Hong Kong, raising a net of 0.828 billion Hong Kong dollars.

cls.cnDec 22 19:12 ET

Hong Kong stock market morning report on December 23: Biden signed a bill to prevent the USA government from "shutting down". The performance of China Concept Stocks shows divergence.

① Biden signed an emergency funding bill to prevent a "shutdown" of the USA government. ② The USA's November core PCE price index rose 2.8% year-on-year, which was lower than expected. ③ The three major stock indexes in the USA opened lower and closed higher last Friday, while China Concept Stocks showed mixed performance. ④ NYMEX Henry Hub Natural Gas Futures rose more than 14% last week. ⑤ Federal Reserve's Goolsbee stated that interest rates may decline within 12 to 18 months.

cls.cnDec 22 18:05 ET

CanSino Biologics Inc. (688185.SH): Some controlling shareholders collectively used approximately 5.6705 million Hong Kong dollars to increase their Shareholding by 0.278 million shares Listed in Hong Kong.

Gelonghui reported on December 20 that CanSino Biologics Inc. (688185.SH) announced the receipt of a notification letter regarding the completion of the shareholding plan from certain controlling shareholders, XUEFENGYU (Yu Xuefeng), Zhu Tao, SHOUBAICHAO (Chao Shoubai), as well as Executive Director and senior management personnel Wang Jing. During the implementation period of this shareholding plan, based on their determination of the securities market, arrangements for funding the shareholding, and the shareholding window period, XUEFENGYU (Yu Xuefeng), Zhu Tao, and SHOUBAICHAO (Chao Shoubai) each increased their holdings in the company by 100,000 shares and 110,000 shares respectively.

Gelonghui FinanceDec 20 04:35 ET